Cruciferous Vegetable Intake and Histone Status in Screening Colonoscopy Patients
NCT ID: NCT01344330
Last Updated: 2020-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
108 participants
OBSERVATIONAL
2012-01-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Screening colonoscopy patients
Men and women age 50 to 75 scheduled for screening colonoscopy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* off NSAID or aspirin therapy in accordance with OHSU endoscopy clinic guidelines
* INR 0.90-1.20
* hemoglobin ≥ 13.5 (men) or 12.0 (women)
* platelets ≥100,000/μL
* Chem screen results within normal limits
* negative (serum or urine) pregnancy test done ≤7 days prior to colonoscopy for women of childbearing potential only
* ASA performance status \<2
Exclusion Criteria
* current smoker
* medical history of chronic obstructive pulmonary disease
* current oral steroid therapy
* current therapy with valproate or other pharmacological drugs associated with HDAC inhibition
* use of oral antibiotics within 3 months prior to entry into study
* significant active medical illness which in the opinion of the investigator would preclude collection/interpretation of colon tissue
* diagnosis of hemophilia, van Willebrand's disease or other bleeding disorder
* use of warfarin or other blood thinning agents
* inflammatory bowel disease.
50 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oregon Health and Science University
OTHER
National Cancer Institute (NCI)
NIH
Texas A&M University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roderick Dashwood
Professor, Texas A&M HSC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rod Dashwood, PhD
Role: PRINCIPAL_INVESTIGATOR
Oregon State University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon Health & Science University
Portland, Oregon, United States
Countries
Review the countries where the study has at least one active or historical site.